RT Journal Article
SR Electronic
T1 First-in-human demonstration of splenic ultrasound stimulation for non-invasively controlling inflammation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.14.20153528
DO 10.1101/2020.07.14.20153528
A1 Graham, Rachel S.
A1 Zachs, Daniel P.
A1 Cotero, Victoria
A1 D’Agostino, Catherine
A1 Ntiloudi, Despoina
A1 Kaiser, Claire R.W.
A1 Graf, John
A1 Wallace, Kirk
A1 Ramdeo, Richard
A1 Coleman, Thomas R.
A1 Ashe, Jeffrey
A1 Pellerito, John
A1 Tracey, Kevin J.
A1 Binstadt, Bryce A.
A1 Chavan, Sangeeta S.
A1 Zanos, Stavros
A1 Puleo, Christopher
A1 Peterson, Erik
A1 Lim, Hubert H.
YR 2020
UL http://medrxiv.org/content/early/2020/09/10/2020.07.14.20153528.abstract
AB Hyperinflammation and uncontrolled cytokine release in infections and autoimmune diseases require therapy to reduce the innate immune response. Here, we present first in-human data showing reduction in pro-inflammatory cytokine release with ultrasound stimulation of the spleen in healthy subjects and in rheumatoid arthritis patients. Single cell RNA sequencing reveals a decrease in IL-1β and IL-8 transcript levels in circulating monocytes. There is also a down regulation of pathways involved in TNF and IL-6 production, and IFNγ- and NFκB-regulated genes. Additional pre-clinical studies reveal that ultrasound can boost B cell activation and antibody production. Splenic ultrasound offers a new non-invasive therapy for treating hyperinflammation without compromising the adaptive immune response.Competing Interest StatementK.W., J.G., J.A., V.C., C.P. are employees of GE and declare that GE has filed U.S. and international patent applications describing methods, devices, and systems for precision organ-based ultrasound neuromodulation. R.S.G., D.P.Z., C.R.W.K., H.H.L are affiliated with University of Minnesota and declare that they have filed U.S. and international patent applications describing methods, devices, and systems for peripheral nerve and end-organ modulation. Feinstein authors have received research funding from GE to investigate the effects of splenic ultrasound in healthy subjects. Dr. Hubert Lim holds equity in, and serves as Chief Scientific Officer of, SecondWave Systems, which is developing wearable ultrasound stimulation technologies for end-organ and neural modulation. Mr. Daniel Zachs holds equity in, and is an employee of, SecondWave Systems. These interests for Dr. Lim and Mr. Zachs have been reviewed and managed by the University of Minnesota in accordance with its Conflict of Interest policies. All other authors declare that they have no competing interests.Clinical TrialNCT03548116, NCT03690466Funding StatementListed authors from GE Research, Feinstein Institutes for Medical Research and North Shore University Hospital have received research funding from GE to investigate the effects of splenic ultrasound stimulation in healthy subjects. Listed authors from the University of Minnesota received funding from DARPA ElectRx Program (N660011824018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For the splenic ultrasound study involving healthy human subjects(NCT03548116), the trial was carried out in accordance with International Conference on Harmonisation Good Clinical Practice (ICH GCP) and the United States Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 812). The protocol, informed consent form, recruitment materials, and all participant materials were submitted and approved by the Institutional Review Board (IRB) at Northwell Health. For the clinical study listed at RA patients (NCT03690466), the protocol, informed consent form, recruitment materials, and all participant materials were submitted and approved by the University of Minnesota Institutional Review Board (IRB) and monitored by CTSI in accordance with its institutionally approved monitoring plan.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData associated with this study are presented in this paper or supplemental document. The RNA-seq data presented in this paper will soon be deposited in the Gene Expression Omnibus database. Other data or methods such as that used for bioinformatic analyses or visualization are available upon reasonable request.